These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 24771924)

  • 1. Prenatal Clinical Assessment of sFlt-1 (Soluble fms-like Tyrosine Kinase-1)/PlGF (Placental Growth Factor) Ratio as a Diagnostic Tool for Preeclampsia, Pregnancy-induced Hypertension, and Proteinuria.
    Lehnen H; Mosblech N; Reineke T; Puchooa A; Menke-Möllers I; Zechner U; Gembruch U
    Geburtshilfe Frauenheilkd; 2013 May; 73(5):440-445. PubMed ID: 24771924
    [No Abstract]   [Full Text] [Related]  

  • 2. A Second Trimester Prediction Algorithm for Early-Onset Hypertensive Disorders of Pregnancy Occurrence and Severity Based on Soluble fms-like Tyrosine Kinase 1 (sFlt-1)/Placental Growth Factor (PlGF) Ratio and Uterine Doppler Ultrasound in Women at Risk.
    Chirilă CN; Mărginean C; Ghiga DV; Voidăzan S; Chirilă PM; Gliga ML
    Children (Basel); 2024 Apr; 11(4):. PubMed ID: 38671685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Onset threshold of the plasma levels of soluble fms-like tyrosine kinase 1/placental growth factor ratio for predicting the imminent onset of preeclampsia within 4 weeks after blood sampling at 19-31 weeks of gestation.
    Ohkuchi A; Hirashima C; Takahashi K; Suzuki H; Matsubara S; Suzuki M
    Hypertens Res; 2013 Dec; 36(12):1073-80. PubMed ID: 23966056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of Kryptor and Elecsys® immunoassay sFlt-1/PlGF ratio on early diagnosis of preeclampsia and fetal growth restriction: A case-control study.
    Simón E; Herraiz I; Villalaín C; Gómez-Arriaga PI; Quezada MS; López-Jiménez EA; Galindo A
    Pregnancy Hypertens; 2020 Apr; 20():44-49. PubMed ID: 32172169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble fms-like tyrosine kinase-1 and placental growth factor kinetics during and after pregnancy in women with suspected or confirmed pre-eclampsia.
    Saleh L; van den Meiracker AH; Geensen R; Kaya A; Roeters van Lennep JE; Duvekot JJ; Verdonk K; Steegers EAP; Russcher H; Danser AHJ; Visser W
    Ultrasound Obstet Gynecol; 2018 Jun; 51(6):751-757. PubMed ID: 28600845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The soluble fms-like tyrosin kinase-1 (sFLT-1) to placental growth factor (PIGF) ratio as a possible indicator for the severity of preeclampsia - single institution experience.
    Müller A; Horvat V; Vulin M; Mandić S; Šerić V; Vidosavljević D
    Med Glas (Zenica); 2019 Feb; 16(1):53-59. PubMed ID: 30680983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between placental weight and angiogenic markers sFlt-1 and PlGF in women with preeclampsia and fetal growth restriction.
    Lorenz-Meyer LA; Frank L; Sroka D; Busjahn A; Henrich W; Verlohren S
    Pregnancy Hypertens; 2022 Jun; 28():149-155. PubMed ID: 35453103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of the sFlt-1/PlGF ratio to rule out preeclampsia requiring delivery in women with suspected disease. Is the evidence reproducible?
    Sabrià E; Lequerica-Fernández P; Ganuza PL; Ángeles EE; Escudero AI; Martínez-Morillo E; Alvárez FV
    Clin Chem Lab Med; 2018 Jan; 56(2):303-311. PubMed ID: 28841572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intermanufacturer assessment of diagnostic performance of angiogenic ratio vs glycosylated fibronectin in women with suspected pre-eclampsia.
    Wah IYM; Sahota DS; Wong NKL; Lee NMW; Liu CJ; Lau CSL; Leung HHY; Poon LC
    Ultrasound Obstet Gynecol; 2024 Nov; 64(5):620-625. PubMed ID: 39344277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive value of sFlt-1, PlGF, sFlt-1/PlGF ratio and PAPP-A for late-onset preeclampsia and IUGR between 32 and 37 weeks of pregnancy.
    Birdir C; Droste L; Fox L; Frank M; Fryze J; Enekwe A; Köninger A; Kimmig R; Schmidt B; Gellhaus A
    Pregnancy Hypertens; 2018 Apr; 12():124-128. PubMed ID: 29674192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analytical evaluation of the novel soluble fms-like tyrosine kinase 1 and placental growth factor assays for the diagnosis of preeclampsia.
    van Helden J; Weiskirchen R
    Clin Biochem; 2015 Nov; 48(16-17):1113-9. PubMed ID: 26129879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elecsys® and Kryptor immunoassays for the measurement of sFlt-1 and PlGF to aid preeclampsia diagnosis: are they comparable?
    Stepan H; Hund M; Dilba P; Sillman J; Schlembach D
    Clin Chem Lab Med; 2019 Aug; 57(9):1339-1348. PubMed ID: 31323000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of sFlt-1/PlGF ratio and feto-maternal Doppler for the prediction of adverse perinatal outcome in late-onset pre-eclampsia.
    Graupner O; Karge A; Flechsenhar S; Seiler A; Haller B; Ortiz JU; Lobmaier SM; Axt-Fliedner R; Enzensberger C; Abel K; Kuschel B
    Arch Gynecol Obstet; 2020 Feb; 301(2):375-385. PubMed ID: 31734756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of preeclampsia and induced delivery at <34 weeks gestation by sFLT-1 and PlGF in patients with abnormal midtrimester uterine Doppler velocimetry: a prospective cohort analysis.
    Stubert J; Ullmann S; Bolz M; Külz T; Dieterich M; Richter DU; Reimer T
    BMC Pregnancy Childbirth; 2014 Aug; 14():292. PubMed ID: 25169665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Validation of the sFlt-1:PlGF Ratio as a Biomarker for Preeclampsia Diagnosis in a High-Risk Obstetrics Unit.
    Miller JJ; Higgins V; Melamed N; Hladunewich M; Ma L; Yip PM; Fu L
    J Appl Lab Med; 2023 May; 8(3):457-468. PubMed ID: 36869760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Threshold of soluble fms-like tyrosine kinase 1/placental growth factor ratio for the imminent onset of preeclampsia.
    Ohkuchi A; Hirashima C; Matsubara S; Takahashi K; Matsuda Y; Suzuki M
    Hypertension; 2011 Nov; 58(5):859-66. PubMed ID: 21947468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of a new and automated electrochemiluminescence immunoassay for plasma sFlt-1 and PlGF levels in women with preeclampsia.
    Ohkuchi A; Hirashima C; Suzuki H; Takahashi K; Yoshida M; Matsubara S; Suzuki M
    Hypertens Res; 2010 May; 33(5):422-7. PubMed ID: 20150910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary placental growth factor in preeclampsia and fetal growth restriction: An alternative to circulating biomarkers?
    Zhang K; Zen M; Popovic NL; Lee VW; Alahakoon TI
    J Obstet Gynaecol Res; 2019 Sep; 45(9):1828-1836. PubMed ID: 31257726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PP051. Prediction of preeclampsia with the sFlt-1/PLGF ratio: impact of the slope of repeated measurements.
    Schoofs K; Engels T; Pape J; Henrich W; Stepan H; Verlohren S
    Pregnancy Hypertens; 2012 Jul; 2(3):269. PubMed ID: 26105374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Value of second trimester maternal serum sFlt-1, PlGF and their ratio in the prediction of preeclampsia].
    Gao J; Shen J; Jiang Y; Zhou X; Qi H; Liu X; Liu J; Yang J; Bian X
    Zhonghua Fu Chan Ke Za Zhi; 2014 Jan; 49(1):22-5. PubMed ID: 24694913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.